Himax has been on fire lately. In the past six months alone, the company’s stock price has rocketed 67.4%, reaching $9.29 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at hvac and water systems stocks, starting with Trane Technologies (NYSE:TT).
What a brutal six months it’s been for Dave & Buster's. The stock has dropped 36% and now trades at $19.30, rattling many shareholders. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the inspection instruments industry, including Keysight (NYSE:KEYS) and its peers.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how AutoZone (NYSE:AZO) and the rest of the auto parts retailer stocks fared in Q4.
Looking back on professional tools and equipment stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Nordson (NASDAQ:NDSN) and its peers.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at UnitedHealth (NYSE:UNH) and its peers.
Let’s dig into the relative performance of Bumble (NASDAQ:BMBL) and its peers as we unravel the now-completed Q4 consumer subscription earnings season.
Over the past six months, Sirius XM’s stock price fell to $23.99. Shareholders have lost 18.1% of their capital, which is disappointing considering the S&P 500 has climbed by 6.2%. This may have investors wondering how to approach the situation.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.